COMPANY

EvON Medics

HQ: Ellicott City, MD source · evonmedics.com ↗ · Mid-Atlantic

Location: Ellicott City, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Opioid Use Disorder Early Alzheimer's Disease alzheimer's disease Chronic Pain Low Back Pain Substance Use Disorders Alcohol Use Disorder Cocaine Use Disorder Methamphetamine-dependence Mild Cognitive Impairment Memory Impairment Moderate Opioid Use Disorder Severe Opioid Use Disorder Withdrawal Symptoms Craving Negative Affectivity

5Trials (company is sponsor)19NIH grants

Timeline

Oct 23, 2024 Trial start Phase 2: Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P) source ↗
Jul 7, 2023 Trial start Phase 2: Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders source ↗
Apr 27, 2023 Trial start Phase 1: Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain source ↗
Nov 15, 2021 Trial start Phase 2: Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease source ↗
Mar 26, 2021 Trial start Phase 2: Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06671132	Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)	Phase 2	Recruiting	Oct 23, 2024	Nov 30, 2025 (estimated)
NCT06434818	Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders	Phase 2	Unknown status (ClinicalTrials.gov)	Jul 7, 2023	Mar 31, 2025 (estimated)
NCT06218407	Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain	Phase 1	Completed	Apr 27, 2023	Sep 15, 2023 (actual)
NCT05122598	Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease	Phase 2	Unknown status (ClinicalTrials.gov)	Nov 15, 2021	Apr 1, 2023 (estimated)
NCT04850664	Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder	Phase 2	Unknown status (ClinicalTrials.gov)	Mar 26, 2021	Nov 30, 2022 (estimated)

NIH awards 19

Annual award amounts. Total $14.0M.

May 6, 2025 NIH award 5R44AG082621-03 FY2025: $1,249,244 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Portab source ↗
Mar 6, 2025 NIH award 5R44NS125745-03 FY2025: $1,280,870 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Comput source ↗
Jul 24, 2024 NIH award 4R44AG082621-02 FY2024: $1,249,244 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Portab source ↗
Jun 13, 2024 NIH award 5R44DA056156-03 FY2024: $1,219,088 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. The Development and Evaluation of En source ↗
Mar 11, 2024 NIH award 4R44NS125745-02 FY2024: $1,349,130 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Comput source ↗
Jul 19, 2023 NIH award 1R44AG082621-01 FY2023: $448,887 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Portable source ↗
Jun 22, 2023 NIH award 4R44DA056156-02 FY2023: $1,318,829 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. The Development and Evaluation of En source ↗
Feb 3, 2023 NIH award 3R44DA056156-01S1 FY2023: $55,000 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. The Development and Evaluation of Enh source ↗
Sep 19, 2022 NIH award 1R44NS125745-01A1 FY2022: $499,999 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Comput source ↗
Aug 12, 2022 NIH award 3R44AG061981-04S2 FY2022: $98,280 awarded for that fiscal year; activity R44 (SBIR); PI SETH, SUMEET; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computerized Olfacto source ↗
Jun 2, 2022 NIH award 3R44AG061981-04S1 FY2022: $50,000 awarded for that fiscal year; activity R44 (SBIR); PI SETH, SUMEET; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computerized Olfacto source ↗
May 26, 2022 NIH award 5R44AG061981-04 FY2022: $1,245,116 awarded for that fiscal year; activity R44 (SBIR); PI SETH, SUMEET; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computerized Olfact source ↗
Apr 27, 2022 NIH award 1R44DA056156-01 FY2022: $330,680 awarded for that fiscal year; activity R44 (SBIR); PI NWAOKOBIA, CHARLES CHIEDU; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. The Development and Evaluation of Enha source ↗
Aug 16, 2021 NIH award 5R44DA049616-03 FY2021: $859,103 awarded for that fiscal year; activity R44 (SBIR); PI SETH, SUMEET; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computerized Chemosen source ↗
Apr 29, 2021 NIH award 2R44AG061981-03A1 FY2021: $1,247,784 awarded for that fiscal year; activity R44 (SBIR); PI SETH, SUMEET; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computerized Olfa source ↗
Sep 23, 2020 NIH award 2R44DA049616-02 FY2020: $820,883 awarded for that fiscal year; activity R44 (SBIR); PI SETH, SUMEET; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computerized Chemosen source ↗
Sep 18, 2019 NIH award 1R43DA049616-01 FY2019: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI LAWSON, WILLIAM BRADFORD; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computeri source ↗
Jun 20, 2019 NIH award 5R43AG061981-02 FY2019: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI SETH, SUMEET; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computerized Olfactor source ↗
Sep 17, 2018 NIH award 1R43AG061981-01 FY2018: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI SETH, SUMEET; recipient as written: EVON MEDICS, LLC, ELKRIDGE, MD. Development and Evaluation of Computerized Olfactor source ↗